Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Cannabis reduces blood pressure in older adults, according to Ben-Gurion University researchers

Beer-Sheva, Israel…February 8, 2021 – A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults. The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect…
Read More

New Features

As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More

$2.7 million awarded for medical marijuana research in Colorado

The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More

More Treatment Options, Better Patient Outcomes

As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment.  In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness

When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More

Leave a Comment

You must be logged in to post a comment.